Business Context and Reporting Period
Company: Insight Molecular Diagnostics Inc. (IMDX)
Filing Type: Form 8-K (Current Report)
Date of Report: February 20, 2026
Reporting Period: Single event date (February 20, 2026)
The Company entered into a Specimen Collection Agreement with Quest Diagnostics Incorporated to support its GraftAssureCore™ test, a blood test measuring donor-derived cell-free DNA (dd-cfDNA) using a PCR-based platform.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document reports a material definitive agreement rather than periodic financial results.
Material Changes
- New Agreement: Execution of a Specimen Collection Agreement with Quest Diagnostics on February 20, 2026.
- Service Scope: Quest Diagnostics will provide specimen collection services for potential patient registrants of the GraftAssureCore™ test.
- Financial Terms: The Company will pay certain fees to Quest for services rendered; specific fee amounts are not disclosed in this summary.
- Future Negotiations: Both parties agreed to use commercially reasonable efforts to negotiate additional rights to the GraftAssure technology for a specified period.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the strategic partnership to facilitate specimen collection for the Company's diagnostic test. The full text of the agreement is intended to be filed as an exhibit to a subsequent periodic report or an amendment to this 8-K.
Risks and Contingencies: The description of the agreement is qualified by reference to the full text of the Agreement. No specific risks or contingencies are detailed in this excerpt beyond the standard reliance on the full contract terms.
Investor Verification Checklist
- Verify the specific fee structure and payment terms in the full Specimen Collection Agreement (to be filed as an exhibit).
- Confirm the duration of the agreement and the specific "specified period" for negotiating additional technology rights.
- Review the definition of "commercially reasonable efforts" regarding the negotiation of additional GraftAssure technology rights.
- Monitor subsequent filings for the full text of the agreement referenced in Item 1.01.